Dr. Nabhan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
974 Bristol Dr
Deerfield, IL 60015Phone+1 312-927-3327
Education & Training
- Loyola Quinlan School of BuisnessMBA, Health Care Management, Magna Cum Laude, 2014 - 2016
- McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1999 - 2002
- Loyola University Medical CenterResidency, Internal Medicine, 1995 - 1998
- Damascus University Faculty of MedicineClass of 1991
Certifications & Licensure
- FL State Medical License 2008 - 2026
- IL State Medical License 1995 - 2026
- CA State Medical License 2015 - 2025
- IN State Medical License 1999 - 2025
- WI State Medical License 1997 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- National Board of Physicians and Surgeons Hematology
- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- Chicago Top Doctors 2016
- Regional Top Doctor Castle Connolly, 2014
- Top MD Consumers Checkbook
Clinical Trials
- GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere Start of enrollment: 2006 Jan 01
- Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer Start of enrollment: 2006 Dec 01
- Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC) Start of enrollment: 2007 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 17 citationsUsing Response Evaluation Criteria in Solid Tumors in real-world evidence cancer research.Bruce A. Feinberg, Murtuza Bharmal, Andrew J Klink, Chadi Nabhan, Hemant Phatak
Future Oncology. 2018-05-31 - 47 citationsPhase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years oldSimrit Parmar, Lynn M. Rundhaugen, Larry Boehlke, Mary Beth Riley, Chadi Nabhan
Leukemia Research. 2004-09-01 - 119 citationsReal world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United StatesAnthony R. Mato, Meghan C. Thompson, John N. Allan, Danielle M. Brander, John M. Pagel
Haematologica. 2018-09-01
Journal Articles
- Rethinking Clinical Trials Reform During the COVID-19 PandemicChadi Nabhan, Toni K Choueiri, JAMA Oncology
Abstracts/Posters
- Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community PracticesChadi Nabhan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Adverse Events in Elderly Hodgkin Lymphoma Patients Treated with Pembrolizumab or Nivolumab in the Real WorldChadi Nabhan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular TherapiesChadi Nabhan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Frequency and causes of oncologists’ burnout in community practices.2019 ASCO Annual Meeting - 6/1/2019
- Patient-Reported Outcome Labeling for Malignant Hematology Drugs Approved in the United States: 2011-20172018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Treatment Patterns and Outcomes of Relapsed/Refractory Peripheral T-Cell Lymphoma (RR-PTCL) Patients Treated in the Community Oncology Setting2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Authored Content
- Rethinking Clinical Trials Reform During the COVID-19 PandemicAugust 2020
- Rethinking Clinical Trials Reform During the COVID-19 PandemicAugust 2020
Press Mentions
- Caris Life Sciences to Showcase Research Highlighting the Clinical Value of Comprehensive Molecular Profiling at the American Association for Cancer Research Annual MeetingApril 14th, 2023
- The Caris Precision Oncology Alliance Welcomes University of Chicago Medicine Comprehensive Cancer CenterMarch 8th, 2023
- Caris Life Sciences to Showcase Extensive Research with Leading Cancer Centers at ASCO Gastrointestinal Cancers Symposium 2023 Reflecting Its Commitment to Improving Outcomes for PatientsJanuary 18th, 2023
- Join now to see all
Professional Memberships
- Member
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: